Preclinical human models and emerging therapeutics for advanced systemic mastocytosis

Michel Arock, Ghaith Wedeh, Gregor Hoermann, Siham Bibi, Cem Akin, Barbara Peter, Karoline V. Gleixner, Karin Hartmann, Joseph H. Butterfield, Dean D. Metcalfe, and Peter Valent

Disclosures: M.A. holds a patent for ROSA cells and received research grants from Blueprint Medicines and from Deciphera Pharmaceuticals, as well as honorarium from Deciphera Pharmaceuticals. G.H. received research grants and honoraria from Novartis. C.A. holds a patent for LAD-2 cells, and has consultancy agreements with Novartis, Blueprint Medicines, and Deciphera. K.H. received research grants from Euroimmun and honoraria from ALK-Abello, Blueprint Medicines, Deciphera Pharmaceuticals, Novartis and Shire. J.H.B. receives royalty payments for the licensing of HMC-1.1 and HMC-1.2 cells through Milliporesigma. P.V. holds a patent for ROSA cells and received research grants and honoraria from Novartis, Ariad and Celgene as well as honoraria from Pfizer, BMS, Blueprint Medicines and Deciphera Pharmaceuticals.

Contributions: MA and PV wrote the manuscript. BP and KVG designed and conducted the in vitro experiments with KIT-tyrosine kinase inhibitors and analyzed the data. SB and GW designed and conducted the in vitro experiments with STAT inhibitors and analyzed the data. SB designed and conducted the in vivo experiments and analyzed the data. CA, JHB, GH, KH, and DDM provided essential information on human mast cell lines and revised the manuscript. All co-authors approved the submission of the manuscript in its final form.